A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This phase3 study is a randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of Lemzoparlimab for injection in combination with AZA versus AZA monotherapy as first-line therapy in treatment-naïve subjects with intermediate- and high-risk MDS.
Epistemonikos ID: ff3dae7af4d2f9fe5ea5aee9916381bfeffc42f3
First added on: Feb 19, 2024